Skip to main content

hematologic malignancies

Research Reports
02/06/2023
Petty et al evaluated the belief in research, religious coping, and willingness to participate in clinical trials by African American patients with hematologic malignancies. The basis for their exploration is that, while the AA population has...
Petty et al evaluated the belief in research, religious coping, and willingness to participate in clinical trials by African American patients with hematologic malignancies. The basis for their exploration is that, while the AA population has...
Petty et al evaluated the belief...
02/06/2023
Journal of Clinical Pathways
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Videos
12/17/2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses...
12/17/2020
Journal of Clinical Pathways
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
Videos
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways
Conference Coverage
12/09/2020
Journal of Clinical Pathways
Conference Coverage
12/09/2020
Journal of Clinical Pathways
Conference Coverage
12/06/2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with...
12/06/2020
Journal of Clinical Pathways
Conference Coverage
12/06/2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study...
12/06/2020
Journal of Clinical Pathways